All questionsSpecific populations: Tremfya (guselkumab), all indications4 questions · 1 sourcePregnancy and breastfeedingIs Tremfya safe during pregnancy?“Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to TREMFYA during pregnancy. Patients should be encouraged to enroll in the registry by visiting www.mothertobaby.org/ongoing-study/ tremfya-guselkumab, by calling 1-877-311-8972, or emailing MotherToBaby@ health.ucsd.edu.” (opens the source at this quote in a new tab)CopyFlag“Available data from literature, post-marketing reports, and ongoing pregnancy registry with TREMFYA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Monoclonal antibodies are actively transported across the placenta (see Clinical Considerations).” (opens the source at this quote in a new tab)CopyFlag“Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses and peaks during the third trimester. Therefore, TREMFYA may be present in infants exposed in utero. The potential clinical impact of guselkumab exposure in infants exposed in utero should be considered.” (opens the source at this quote in a new tab)CopyFlagCan you breastfeed while taking Tremfya?“There are no data on the presence of guselkumab in human milk, the effects on the breastfed infant, or the effects on milk production. Guselkumab was not detected in the milk of lactating cynomolgus monkeys. Endogenous maternal IgG and monoclonal antibodies are transferred into human milk. The effects of local gastrointestinal exposure and the extent of systemic exposure in the breastfed infant to guselkumab are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TREMFYA and any potential adverse effects on the breastfed infant from TREMFYA or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsIs Tremfya dosing different for older adults?“Of the 6418 subjects with plaque psoriasis, psoriatic arthritis, ulcerative colitis, or Crohn’s disease exposed to TREMFYA, a total of 489 subjects were 65 years or older, and 55 subjects were 75 years or older. Clinical studies of TREMFYA, within each indication, did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects. No clinically meaningful differences in the pharmacokinetics of guselkumab were observed based on age [see Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“No apparent differences in clearance were observed in subjects ≥ 65 years of age compared to subjects < 65 years of age, suggesting no dose adjustment is needed for elderly subjects.” (opens the source at this quote in a new tab)CopyFlagDoes Tremfya need dose adjustment for kidney or liver impairment?“No specific trials have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of guselkumab.” (opens the source at this quote in a new tab)CopyFlag